Who are Ranibizumab + deferred laser's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lucentis (Treat and extend), Lucentis every 4 weeks, Lucentis (ranibizumab), Anti-VEGF drug, aflibercept + FOLFIRI, Lucentis every 12 weeks.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ranibizumab-deferred-laser.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ranibizumab + deferred laser — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ranibizumab + deferred laser (Ranibizumab + deferred laser) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anti-VEGF agent. Area: Ophthalmology.

phase 3 anti-VEGF agent VEGF-A Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Ranibizumab + deferred laser (Ranibizumab + deferred laser) — Jaeb Center for Health Research. Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) by binding to its receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ranibizumab + deferred laser TARGET	Ranibizumab + deferred laser	Jaeb Center for Health Research	phase 3	anti-VEGF agent	VEGF-A
Lucentis (Treat and extend)	Lucentis (Treat and extend)	Retinal Consultants of Arizona	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A
Lucentis every 4 weeks	Lucentis every 4 weeks	Retinal Consultants of Arizona	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A
Lucentis (ranibizumab)	Lucentis (ranibizumab)	Samsung Bioepis Co., Ltd.	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Anti-VEGF drug	Anti-VEGF drug	Xiaodong Sun	marketed	Anti-VEGF	VEGF-A
aflibercept + FOLFIRI	aflibercept + FOLFIRI	CR-CSSS Champlain-Charles-Le Moyne	marketed	VEGF inhibitor (fusion protein) + chemotherapy combination	VEGF-A, VEGF-B, PlGF (aflibercept component); topoisomerase I and thymidylate synthase (FOLFIRI component)
Lucentis every 12 weeks	Lucentis every 12 weeks	Retinal Consultants of Arizona	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (anti-VEGF agent class)

Hawaii Pacific Health · 1 drug in this class
Jaeb Center for Health Research · 1 drug in this class
Moorfields Eye Hospital NHS Foundation Trust · 1 drug in this class
Novartis · 1 drug in this class
ONL Therapeutics · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ranibizumab + deferred laser — Competitive Intelligence Brief. https://druglandscape.com/ci/ranibizumab-deferred-laser. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab